PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes

Radiotherapy and Oncology

Volumn 116, Issue 2, 2015, Pages 281-286

  Even, Aniek J G ^a   Van Der Stoep, Judith ^a   Zegers, Catharina M L ^a   Reymen, Bart ^a   Troost, Esther G C ^a,b   Lambin, Philippe ^a   Van Elmpt, Wouter ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

Author keywords

Dose painting; FDG; HX4; NSCLC; Positron emission tomography; Radiotherapy

Indexed keywords

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; COMPARATIVE STUDY; FEMALE; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING SYSTEM; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 84953840222     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2015.07.013     Document Type: Article

References (48)

1. A. Aupérin, C. Le Péchoux, E. Rolland, and et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer J Clin Oncol 28 2010 2181 2190
2. F.M. Kong, R.K. Ten Haken, M.J. Schipper, and et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study Int J Radiat Oncol Biol Phys 63 2005 324 333
3. M. Machtay, K. Bae, B. Movsas, and et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group Int J Radiat Oncol Biol Phys 82 2012 425 434
4. C.C. Ling, J. Humm, S. Larson, and et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality Int J Radiat Oncol Biol Phys 47 2000 551 560
5. P. Lambin, S.F. Petit, Aerts H.J. The, E.S.T.R.O. Breur Lecture, and et al. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer Radiother Oncol 2010 2009 145 152
6. S.F. Petit, A.L. Dekker, R. Seigneuric, and et al. Intra-voxel heterogeneity influences the dose prescription for dose-painting with radiotherapy: a modelling study Phys Med Biol 54 2009 2179 2196
7. S.M. Bentzen Theragnostic imaging for radiation oncology: dose-painting by numbers Lancet Oncol 6 2005 112 117
8. W. van Elmpt, D. De Ruysscher, A. van der Salm, and et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer Radiother Oncol 104 2012 67 71
9. I. Madani, W. Duthoy, C. Derie, and et al. Positron Emission Tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer Int J Radiat Oncol Biol Phys 68 2007 126 135
10. V.R. Bollineni, E.M. Wiegman, J. Pruim, H.J. Groen, and J.A. Langendijk Hypoxia imaging using positron emission tomography in non-small cell lung cancer: implications for radiotherapy Cancer Treat Rev 38 2012 1027 1032
11. D. Zips, S. Böke, T. Kroeber, and et al. Prognostic value of radiobiological hypoxia during fractionated irradiation for local tumor control Strahlenther Onkol 187 2011 306 310
12. L.J. Dubois, N.G. Lieuwes, M.H. Janssen, and et al. Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging Proc Natl Acad Sci USA 108 2011 14620 14625
13. C.M. Zegers, W. van Elmpt, R. Wierts, and et al. Hypoxia imaging with [18F]HX4 PET in NSCLC patients: defining optimal imaging parameters Radiother Oncol 109 2013 58 64
14. 18F]FMISO in a preclinical tumor model Int J Radiat Oncol Biol Phys 2 2014 22
15. J. van Loon, M.H. Janssen, M. Öllers, and et al. PET imaging of hypoxia using [18F]HX4: a phase I trial Eur J Nucl Med Mol Imaging 37 2010 1663 1668
16. H.J. Aerts, G. Bosmans, A.A. van Baardwijk, and et al. Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study Int J Radiat Oncol Biol Phys 71 2008 1402 1407
17. A. Abramyuk, S. Tokalov, K. Zöphel, and et al. Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer? Radiother Oncol 91 2009 399 404
18. H.J. Aerts, A.A. van Baardwijk, S.F. Petit, and et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan Radiother Oncol 91 2009 386 392
19. H.J. Aerts, P. Lambin, and D.D. Ruysscher FDG for dose painting: a rational choice Radiother Oncol 97 2010 163 164
20. F. Würschmidt, C. Petersen, A. Wahl, J. Dahle, and M. Kretschmer [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes Radiat Oncol 6 2011 44
21. E.G. Troost, J. Bussink, A.L. Hoffmann, O.C. Boerman, W.J. Oyen, and J.H. Kaanders 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors J Nucl Med 51 2010 866 874
22. 18F]FDG-PET/CT Imaging Clin Cancer Res 20 2014 6389 6397
23. R. Boellaard, W.J. Oyen, C.J. Hoekstra, and et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials Eur J Nucl Med Mol Imaging 35 2008 2320 2333
24. M. van Herk, P. Remeijer, and J.V. Lebesque Inclusion of geometric uncertainties in treatment plan evaluation Int J Radiat Oncol Biol Phys 52 2002 1407 1422
25. L. Dubois, W. Landuyt, K. Haustermans, and et al. Evaluation of hypoxia in an experimental rat tumour model by [18F]fluoromisonidazole PET and immunohistochemistry Br J Cancer 91 2004 1947 1954
26. W.J. Koh, K.S. Bergman, J.S. Rasey, and et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography Int J Radiat Oncol Biol Phys 33 1995 391 398
27. J.S. Rasey, W.J. Koh, M.L. Evans, and et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients Int J Radiat Oncol Biol Phys 36 1996 417 428
28. J. van Diessen, J. Belderbos, J.J. Sonke, and et al. Very high radiation dose escalation in NSCLC does not lead to unexpected toxicity: a planned toxicity analysis of the PET-boost study (NCT01024829) J Thorac Oncol 8 2013 S1135
29. J. Belderbos, W. Heemsbergen, M. Hoogeman, K. Pengel, M. Rossi, and J. Lebesque Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy Radiother Oncol 75 2005 157 164
30. J.H. Chang, M. Wada, N.J. Anderson, and et al. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study Acta Oncol 52 2013 1723 1729
31. W. Choi, S.W. Lee, S.H. Park, and et al. Planning study for available dose of hypoxic tumor volume using fluorine-18-labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer Radiother Oncol 97 2010 176 182
32. K. Hendrickson, M. Phillips, W. Smith, L. Peterson, K. Krohn, and J. Rajendran Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance Radiother Oncol 101 2011 369 375
33. I. Toma-Dasu, J. Uhrdin, L. Antonovic, and et al. Dose prescription and treatment planning based on FMISO-PET hypoxia Acta Oncol 51 2012 222 230
34. M.R. Horsman, L.S. Mortensen, J.B. Petersen, M. Busk, and J. Overgaard Imaging hypoxia to improve radiotherapy outcome Nat Rev Clin Oncol 9 2012 674 687
35. F. Dehdashti, M.A. Mintun, J.S. Lewis, and et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM Eur J Nucl Med Mol Imaging 30 2003 844 850
36. S.M. Eschmann, F. Paulsen, M. Reimold, and et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy J Nucl Med 46 2005 253 260
37. 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer Clin Lung Cancer 11 2010 335 340
38. S.G. Peeters, C.M. Zegers, A. Yaromina, W. Van Elmpt, L. Dubois, and P. Lambin Current preclinical and clinical applications of hypoxia PET imaging using 2-nitroimidazoles Q J Nucl Med Mol Imaging 59 2015 39 57
39. P. Vera, P. Bohn, A. Edet-Sanson, and et al. Simultaneous positron emission tomography (PET) assessment of metabolism with (18)F-fluoro-2-deoxy-d-glucose (FDG), proliferation with (18)F-fluoro-thymidine (FLT), and hypoxia with (18)fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study Radiother Oncol 98 2011 109 116
40. T.J. Bradshaw, S. Yip, N. Jallow, L.J. Forrest, and R. Jeraj Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy Int J Radiat Oncol Biol Phys 89 2014 399 405
41. M.E. Trinkaus, R. Blum, D. Rischin, and et al. Imaging of hypoxia with 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy J Med Imaging Radiat Oncol 57 2013 475 481
42. V.R. Bollineni, M.J. Koole, J. Pruim, and et al. Dynamics of tumor hypoxia assessed by (18)F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: Possible implications for radiotherapy treatment planning strategies Radiother Oncol 113 2014 198 203
43. Z. Lin, J. Mechalakos, S. Nehmeh, and et al. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography Int J Radiat Oncol Biol Phys 70 2008 1219 1228
44. R. Rengan, K.E. Rosenzweig, E. Venkatraman, and et al. Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer Int J Radiat Oncol Biol Phys 60 2004 741 747
45. A. van Baardwijk, B. Reymen, S. Wanders, and et al. Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer Eur J Cancer 48 2012 2339 2346
46. A. van Baardwijk, S. Wanders, L. Boersma, and et al. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer J Clin Oncol 28 2010 1380 1386
47. J.D. Bradley, R. Paulus, R. Komaki, and et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study Lancet Oncol 16 2015 187 199
48. J.D. Cox Are the results of RTOG 0617 mysterious? Int J Radiat Oncol Biol Phys 82 2012 1042 1044